<DOC>
	<DOCNO>NCT00010049</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may interfere growth tumor cell may effective treatment recurrent glioma meningioma . PURPOSE : Phase I/II trial study effectiveness imatinib mesylate treat patient progressive , recurrent , unresectable malignant glioma meningioma .</brief_summary>
	<brief_title>Imatinib Mesylate Treating Patients With Recurrent Malignant Glioma Meningioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose imatinib mesylate patient recurrent malignant glioma meningioma . - Determine safety profile drug patient . - Determine pharmacokinetics drug , without concurrent enzyme-inducing anti-epileptic drug ( EIAEDs ) , patient . ( Stratum patient currently take EIAEDs close accrual 05/15/2003 phase I phase II ) - Determine angiogenic activity vivo use functional neuro-imaging study vitro assay serum angiogenic peptide . - Determine efficacy drug , term 6-month progression-free survival objective tumor response , patient . OUTLINE : This multicenter , dose-escalation study . Patients stratify accord concurrent enzyme-inducing anti-epileptic drug use ( yes [ stratum close accrual 05/15/2003 phase I phase II ] v ) . - Phase I ( patient glioma meningioma ) Patients cohorts 1 2 receive oral imatinib mesylate ( STI571 ) daily day 1-28 . Patients cohorts 3-5 receive oral STI571 twice daily day 1 3-28 first course day 1-28 subsequent course . Courses repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos STI571 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II ( patient glioma ) ( glioblastoma multiforme patient exclude 05/15/2003 ) Patients receive oral STI571 MTD determine phase I , 1-2 time daily 4 week . Courses repeat every 4 week absence disease progression unacceptable toxicity . Patients follow survival . PROJECTED ACCRUAL : A total 36 patient accrued phase I study within 6 month total 39 patient accrue phase II study within 6-8 month . ( Glioblastoma multiforme patient exclude phase II 05/13/2003 ) .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent unresectable malignant glioma Glioblastoma multiforme ( phase I ) Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic mix oligoastrocytoma Malignant astrocytoma otherwise specify Gliosarcoma Lowgrade histology subsequent diagnosis malignant glioma allow ( phase I ) OR Histologically confirm recurrent unresectable benign malignant meningioma ( phase I ) No prior intracranial hemorrhage Failed prior radiotherapy Progressive recurrent disease MRI CT scan and/or resection PET thallium scan , MR spectroscopy , surgical documentation require patient receive prior interstitial brachytherapy stereotactic radiosurgery Stable dose steroid 57 day prior MRI CT scan PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : More 8 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL ( transfusion allow ) Hepatic : Bilirubin le 2 time upper limit normal ( ULN ) SGOT le 2 time ULN No significant hepatic disease Renal : Creatinine le 1.5 mg/dL Creatinine clearance least 60 mL/min No significant renal disease Cardiovascular : No significant cardiac disease No deep venous arterial thrombosis within past 6 week Pulmonary : No pulmonary embolism within past 6 week Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 6 month study participation No serious concurrent medical illness No serious active infection No concurrent disease would obscure toxicity alter drug metabolism No malignancy within past 3 year except nonmelanoma skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 week since prior interferon thalidomide recover No concurrent immunotherapy No concurrent prophylactic filgrastim ( GCSF ) Chemotherapy : Recovered prior chemotherapy At least 4 week since prior cytotoxic therapy At least 2 week since prior vincristine At least 6 week since prior nitrosoureas At least 4 week since prior temozolomide At least 3 week since prior procarbazine Prior polifeprosan 20 carmustine implant ( Gliadel wafer ) allow Prior radiosensitizers allow No concurrent chemotherapy Phase I : Prior chemotherapy require anaplastic astrocytoma , anaplastic oligodendroglioma , anaplastic mixed oligoastrocytoma Prior treatment 3 relapse allow Phase II : Prior chemotherapy require Prior treatment 2 relapse allow Endocrine therapy : See Disease Characteristics At least 1 week since prior tamoxifen recover No concurrent anticancer hormonal therapy Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics Recovered prior surgical resection recurrent progressive disease Other : At least 1 week since prior noncytotoxic agent recover At least 1 week since prior tretinoin recover At least 2 week since prior drug affect hepatic metabolism No concurrent investigational agent No concurrent warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult meningioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>adult grade III meningioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>